RecruitingPhase 1NCT05873686

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

Sponsor

Nuvectis Pharma, Inc.

Enrollment

140 participants

Start Date

Oct 26, 2023

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumor Mesothelioma Renal Cancer NSCLC (Non-small Cell Lung Cancer)Non-Small Cell Squamous Lung Cancer Non-small Cell Lung Adenocarcinoma

Summary

This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterations) targets of NXP900.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is a first-in-human study testing a new experimental drug called NXP900 in people with advanced, metastatic, or progressive solid tumours that have no remaining standard treatment options. The main aim is to assess safety and find the right dose. **You may be eligible if...** - You are 18 or older - You have an advanced or metastatic solid tumour that has progressed despite available treatments, or for which no effective treatment exists - You have at least one measurable tumour on imaging - Your overall health is good (ECOG 0–1) **You may NOT be eligible if...** - Your tumour is HER2-positive - You have received radiation therapy to the study measurement site within a specified time frame - You have significant heart problems or other serious medical conditions - Your blood counts or organ function do not meet the required levels Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNXP900

NXP900 is an orally administered SRC/YES1 kinase inhibitor

Locations(12)

Mayo Clinic

Phoenix, Arizona, United States

Sarah Cannon Research Institute at HealthONE

Denver, Colorado, United States

Mayo Clinic

Jacksonville, Florida, United States

University of Chicago

Chicago, Illinois, United States

Mayo Clinic Rochester

Rochester, Minnesota, United States

Oregon Health and Science University

Portland, Oregon, United States

The University of Texas MD Anderson Cancer Center

Houston, Texas, United States

NEXT Oncology Houston

Houston, Texas, United States

NEXT Oncology Dallas

Irving, Texas, United States

NEXT Oncology Virginia

Fairfax, Virginia, United States

Western General Hospital - NHS Lothian

Edinburgh, United Kingdom

The Royal Marsden NHS Foundation and Trust

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05873686

Related Trials

Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome

NCT044310241 location

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

NCT000268841 location

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies

NCT0721383011 locations

A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

NCT0683300813 locations

Study in Advanced Solid Tumor Patients

NCT0730094311 locations